Explore
Validate
Learn
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN2480966 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Complement Decay-Accelerating Factor (CD55) antibody (PE)
- Antibody type
- Monoclonal
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Yellow dye
- Isotype
- IgG
- Antibody clone number
- 67
- Vial size
- 25 tests
Submitted references Regulation of the Helicobacter pylori cellular receptor decay-accelerating factor.
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.
Effect of antihypertensive therapy on left ventricular hypertrophy in essential hypertension.
O'Brien DP, Romero-Gallo J, Schneider BG, Chaturvedi R, Delgado A, Harris EJ, Krishna U, Ogden SR, Israel DA, Wilson KT, Peek RM Jr
The Journal of biological chemistry 2008 Aug 29;283(35):23922-30
The Journal of biological chemistry 2008 Aug 29;283(35):23922-30
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.
van Holten J, Pavelka K, Vencovsky J, Stahl H, Rozman B, Genovese M, Kivitz AJ, Alvaro J, Nuki G, Furst DE, Herrero-Beaumont G, McInnes IB, Musikic P, Tak PP
Annals of the rheumatic diseases 2005 Jan;64(1):64-9
Annals of the rheumatic diseases 2005 Jan;64(1):64-9
Effect of antihypertensive therapy on left ventricular hypertrophy in essential hypertension.
Frohlich ED
Advances in nephrology from the Necker Hospital 1990;19:87-100
Advances in nephrology from the Necker Hospital 1990;19:87-100
No comments: Submit comment
No validations: Submit validation data